[Congressional Record Volume 153, Number 22 (Tuesday, February 6, 2007)]
[Extensions of Remarks]
[Page E267]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

[[Page E267]]


                  PAYING TRIBUTE TO DR. EMIL FREI III

                                 ______
                                 

                           HON. JON C. PORTER

                               of nevada

                    in the house of representatives

                       Tuesday, February 6, 2007

  Mr. PORTER. Madam Speaker, I rise today to honor Dr. Emil Frei III, 
one of the world's leading oncologists, a pioneer in cancer treatment 
and chemotherapy, and a leader in clinical research.
  Dr. Frei's medical career began over 50 years ago in 1948 while 
serving in our country's V-12 program for the United States Navy. Since 
that time he has served as the chief of medicine at the National Cancer 
Institute, associate scientific director head at M.D. Anderson, and 
director and physician-in-chief at the Dana-Farber Cancer Institute. 
Currently, he serves as the physician-in-chief, emeritus at Dana-
Farber. Dr. Frei has the proud honor of being the first Richard and 
Susan Smith Distinguished Professor of Medicine at Harvard Medical 
School
  Since the beginning of his career, Dr. Frei has made many 
contributions to the medical field while serving on the advisory or 
board of directors for non-profit organizations such as Adherex 
Technologies, Angstrom, CaP Cure, Celator Pharmaceuticals, DIAD 
Research, Immunogen, Infinity Pharmaceuticals, Vion Pharmaceuticals, 
Aid for Cancer Research, Cancer Research Institute, Journal of Clinical 
Oncology and the New England Journal of Medicine. In addition to these 
wonderful achievements, he was awarded the Lasker Award, the Kettering 
Prize and the Inaugural Lifetime Achievement Award for his clinical 
research for cancer treatment.
  Dr. Frei not only practiced medicine, but also served as a professor 
of medicine at the University of Texas and Harvard Medical School for 
over 30 years. Dr. Frei also coauthored the first text in medical 
oncology, which is now in its seventh edition.
  Dr. Frei is continuing his research in the Las Vegas area where he 
serves on the chapter board of Southern Nevada Leukemia & Lymphoma 
Society. He has previously served as the chairman of the Cancer and 
Leukemia Group B clinical research group.
  Madam Speaker, I am proud to honor Dr. Frei for his dedication to 
improving the life of others through his service in the medical 
community and advances in the chemotherapy and cancer research. I 
applaud his efforts and wish him the best with his future endeavors.

                          ____________________